News | October 25, 2024
Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Potential of Ayurveda’s contribution in global health system through various innovative practices
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
A committee to be formed to suggest measures for ensuring the safety of healthcare professionals
The emergence of new infections in India is a growing concern
Subscribe To Our Newsletter & Stay Updated
